Ideas, thoughts and commentary about clinical trials and how to make them more efficient by Saloni Dattani, Adam Kroetsch, Manjari Narayan, Ruxandra Teslo, and Witold Więcek.
Would love to hear your guys thoughts on what type of information could be in the world if we maximized measurements in trials rather than repeating multiple similar (or identical) trials simply to test the effects on a single endpoint
Planning to write about this actually! There is both much to gain but also lots of problems to be solved. TL;DR: Existing theory & methodology in clinical trials isn’t enough — think of it as tool development it is like making a leap from bulk RNAseq to single-cell or to spatial. Not a perfect metaphor but the scope change is not trivial.
Planning to write about this actually! There is both much to gain but also lots of problems to be solved. TL;DR: Existing theory & methodology in clinical trials isn’t enough — think of it as tool development; like making a leap from bulk RNAseq to single-cell or spatial transcriptomics. Not a perfect metaphor but the scope change is not trivial.
Awesome!
Would love to hear your guys thoughts on what type of information could be in the world if we maximized measurements in trials rather than repeating multiple similar (or identical) trials simply to test the effects on a single endpoint
Planning to write about this actually! There is both much to gain but also lots of problems to be solved. TL;DR: Existing theory & methodology in clinical trials isn’t enough — think of it as tool development it is like making a leap from bulk RNAseq to single-cell or to spatial. Not a perfect metaphor but the scope change is not trivial.
Planning to write about this actually! There is both much to gain but also lots of problems to be solved. TL;DR: Existing theory & methodology in clinical trials isn’t enough — think of it as tool development; like making a leap from bulk RNAseq to single-cell or spatial transcriptomics. Not a perfect metaphor but the scope change is not trivial.
Kudos!
Everyone discusses the mRNA $750m trial rejected now. Great timing to ask:
What should it cost if we cut off the stupidity now? Let's say the easy to cut stuff. Not a full reform?
Also, the EU+everyone could tell Moderna. "Here's how you can do it for us at $100m and we will approve it".
This way, mRNA vaccines can develop big time. And everyone will see that drug are stopped by dumb requirements rather than honest needs
Maybe the political moment for such an initiative?
Great to see this group of people writing together. Looking forward to this blog!
excited for this!
Subscribed!